Acquisition doubles the Company’s TAM to $8 billion
Expected to be accretive to fiscal 2025 EPS
Conference call at 5:00PM ET to discuss transaction
Acquisition doubles the Company’s TAM to $8 billion
Expected to be accretive to fiscal 2025 EPS
Conference call at 5:00PM ET to discuss transaction
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users
InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT™ platform, with the GastroPlus® and ADMET Predictor® modelling software offered by Simulations Plus.
Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals
Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Partnership will produce an enhanced, validated dermal PBBM/PBPK model to inform product development and bioequivalence decisions.
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use.
Strategic investments in early-stage companies to drive innovation and collaboration
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.
New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models
Partnership aims to integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development
Amparo de la Peña, Vice President of Pharmacometrics at Simulations Plus, will join Jeff Sachs, Pavan Vaddady and Hao Zhu as new board members for 2024.
Fiscal 2023 revenue increased 11% year-over-year to $59.6 million
Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68
Simulations Plus to host its Investor Day on November 14, 2023
Collaboration with regulatory, industry, and academic partners will support and accelerate the development and validation of workflows to conduct virtual bioequivalence studies
Immersive activities helped attendees globally learn and apply best practices for PBPK modeling
Dr. Lukacova’s outstanding contributions to pharmaceutical research and innovation to be recognized with seven others at AAPS PharmSci 360
Elevated ALT levels during clinical trials led researchers to use quantitative systems toxicology (QST) software to better understand potential underlying mechanisms
New functionality, models, and partner data power predictive accuracy from the industry-leading machine learning platform